#$MLYS earnings after close Wed Nov 4, call 4:30 PM ET Wed Nov 4: ir.mineralystx.com/news-events/...
Chart, bull/bear scenarios: justcharts.merlintrader.com#MLYS
Not investment advice.
Chart, bull/bear scenarios: justcharts.merlintrader.com#MLYS
Not investment advice.
November 3, 2026 at 10:57 PM
#$MLYS earnings after close Wed Nov 4, call 4:30 PM ET Wed Nov 4: ir.mineralystx.com/news-events/...
Chart, bull/bear scenarios: justcharts.merlintrader.com#MLYS
Not investment advice.
Chart, bull/bear scenarios: justcharts.merlintrader.com#MLYS
Not investment advice.
🚨 $MLYS
On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update.
On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update.
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 9:20 PM
🚨 $MLYS
On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update.
On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update.
#MLYS Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-reports-third-quarter-2026-financial-results-ytxc4v05010o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-reports-third-quarter-2026-financial-results-ytxc4v05010o.html?utm_source=stocktitan-bluesky&utm_medium=social
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 9:05 PM
#MLYS Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-reports-third-quarter-2026-financial-results-ytxc4v05010o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-reports-third-quarter-2026-financial-results-ytxc4v05010o.html?utm_source=stocktitan-bluesky&utm_medium=social
#$MLYS weekly close $18.18 (-11.5% w/w), below SMA50 $24.78 / below SMA200 $26.99, RSI 29.9. Support $18.11, resistance $24.00. Broad market sell-off Friday.
Oct 27: lorundrostat IP assigned to Mineralys by Tanabe.
New hub updated: www.merlintrader.com/mineralys-th...
Oct 27: lorundrostat IP assigned to Mineralys by Tanabe.
New hub updated: www.merlintrader.com/mineralys-th...
November 1, 2026 at 4:31 PM
#$MLYS weekly close $18.18 (-11.5% w/w), below SMA50 $24.78 / below SMA200 $26.99, RSI 29.9. Support $18.11, resistance $24.00. Broad market sell-off Friday.
Oct 27: lorundrostat IP assigned to Mineralys by Tanabe.
New hub updated: www.merlintrader.com/mineralys-th...
Oct 27: lorundrostat IP assigned to Mineralys by Tanabe.
New hub updated: www.merlintrader.com/mineralys-th...
🚨 $MLYS
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to w...
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to w...
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 8:12 PM
🚨 $MLYS
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to w...
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to w...
#MLYS Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 20…
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2026-financial-fivp12m2yb45.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2026-financial-fivp12m2yb45.html?utm_source=stocktitan-bluesky&utm_medium=social
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Mineralys Therapeutics (MLYS) will report third-quarter 2026 financial results after markets close on November 4, 2026, and host a conference call. The results cover the quarter ended September 30, 2026. The call begins at 4:30 p.m. ET, with a live webcast available through the company website’s Investors section under News & Events.
www.stocktitan.net
October 28, 2026 at 8:05 PM
#MLYS Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 20…
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2026-financial-fivp12m2yb45.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2026-financial-fivp12m2yb45.html?utm_source=stocktitan-bluesky&utm_medium=social
$MLYS Oct 28, 2026: The full Phase 2 Explore-CKD results for lorundrostat are now published in Kidney International: placebo-adjusted systolic blood pressure fell 7.5 mmHg and spot UACR 25.6% at week 4 in 59 participants.
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
Mineralys $MLYS: Lorundrostat, FDA Review And Risks
Mineralys stock analysis: December 22 lorundrostat PDUFA, hypertension trial evidence, Baxfendy competition, cash, debt and commercial risks.
www.merlintrader.com
October 28, 2026 at 4:16 PM
$MLYS Oct 28, 2026: The full Phase 2 Explore-CKD results for lorundrostat are now published in Kidney International: placebo-adjusted systolic blood pressure fell 7.5 mmHg and spot UACR 25.6% at week 4 in 59 participants.
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
#$MLYS shares gained in premarket after Phase 2 Explore-CKD results for lorundrostat were published, showing significant blood pressure and albuminuria reductions. notreload.xyz/xy/mlys-stoc...
Mineralys Stock Rises on Phase 2 Lorundrostat CKD Data
Mineralys Therapeutics shares gained in premarket after Phase 2 Explore-CKD results for lorundrostat were published, showing significant blood pressure and albuminuria reductions.
notreload.xyz
October 28, 2026 at 12:11 PM
#$MLYS shares gained in premarket after Phase 2 Explore-CKD results for lorundrostat were published, showing significant blood pressure and albuminuria reductions. notreload.xyz/xy/mlys-stoc...
$MLYS Oct 28, 2026: The full Phase 2 Explore-CKD results for lorundrostat are now published in Kidney International: placebo-adjusted systolic blood pressure fell 7.5 mmHg and spot UACR 25.6% at week 4 in 59 participants.
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
Mineralys $MLYS: Lorundrostat, FDA Review And Risks
Mineralys stock analysis: December 22 lorundrostat PDUFA, hypertension trial evidence, Baxfendy competition, cash, debt and commercial risks.
www.merlintrader.com
October 28, 2026 at 4:16 PM
$MLYS Oct 28, 2026: The full Phase 2 Explore-CKD results for lorundrostat are now published in Kidney International: placebo-adjusted systolic blood pressure fell 7.5 mmHg and spot UACR 25.6% at week 4 in 59 participants.
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
#MLYS Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-ptmbyqeadkyh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-ptmbyqeadkyh.html?utm_source=stocktitan-bluesky&utm_medium=social
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 28, 2026 at 11:05 AM
#MLYS Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-ptmbyqeadkyh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-ptmbyqeadkyh.html?utm_source=stocktitan-bluesky&utm_medium=social
$LSCC-1 $AMAT-1 $ARVN-1 $FISV-1 $KLAC-1 $SANM-1 $MTH-1 $TXN-1 $AAL-1 $NVST-1 $TSLA-1 $TGTX-1 $WMG-1 $RF-1 $SG-1 $MLYS-1 $SNAP-1 $MDLZ-1 $CVNA-1 $SHOP-1 $QQQM-1 $ECL-1 $CTAS-1 $VRRM-1 $PCAR-1 $EWY-1 $IMVT-1 $NFLX-1 $FOXA-1 $RDDT-1 $B-1 $WYNN-1 $GBTC-1 $SDS-1 $DHI-1 $INCY-1 $PENN-1 $XLY-1 $IGV-1
October 30, 2026 at 8:27 PM
$LSCC-1 $AMAT-1 $ARVN-1 $FISV-1 $KLAC-1 $SANM-1 $MTH-1 $TXN-1 $AAL-1 $NVST-1 $TSLA-1 $TGTX-1 $WMG-1 $RF-1 $SG-1 $MLYS-1 $SNAP-1 $MDLZ-1 $CVNA-1 $SHOP-1 $QQQM-1 $ECL-1 $CTAS-1 $VRRM-1 $PCAR-1 $EWY-1 $IMVT-1 $NFLX-1 $FOXA-1 $RDDT-1 $B-1 $WYNN-1 $GBTC-1 $SDS-1 $DHI-1 $INCY-1 $PENN-1 $XLY-1 $IGV-1
Today is World Opera Day! Enjoy the heart-wrenching short opera "I am worth nothing" that tells the story of two Coahuilteco sisters and their experiences with early Spanish settlers. youtu.be/mLys-feDcK0
I am worth nothing November 16, 2024 at Opera Austin Festival / One Ounce Opera
YouTube video by Adrienne Inglis
youtu.be
October 25, 2026 at 1:39 PM
Today is World Opera Day! Enjoy the heart-wrenching short opera "I am worth nothing" that tells the story of two Coahuilteco sisters and their experiences with early Spanish settlers. youtu.be/mLys-feDcK0
Small-cap stocks with declining money flow, Mon Oct 26th - #$IPST #$XNCR #$XERS #$VIOT #$TAOX #$SLBT #$PGEN #$ORIC #$NBP #$MLYS #$GAIN #$FTH #$DVLT #$CPIX #$BDSX #$AFCG #$GCTS #$SVV #$STC #$CABO - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Monday October 26, 2026 – Crystal Equity Research
crystalequityresearch.com
October 26, 2026 at 10:26 PM
$MLYS Oct 22, 2026, ASN Kidney Week: In a Launch-HTN analysis, lorundrostat lowered placebo-adjusted systolic blood pressure by 9.6 mmHg in patients with chronic kidney disease and 12.2 mmHg in those without, at week 12, and cut UACR...
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
Mineralys $MLYS: Lorundrostat, FDA Review And Risks
Mineralys stock analysis: December 22 lorundrostat PDUFA, hypertension trial evidence, Baxfendy competition, cash, debt and commercial risks.
www.merlintrader.com
October 23, 2026 at 8:41 AM
$MLYS Oct 22, 2026, ASN Kidney Week: In a Launch-HTN analysis, lorundrostat lowered placebo-adjusted systolic blood pressure by 9.6 mmHg in patients with chronic kidney disease and 12.2 mmHg in those without, at week 12, and cut UACR...
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
https://www.merlintrader.com/mineralys-therapeutics-stock-hub/
#MLYS Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Wee…
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-presents-new-lorundrostat-data-in-i28nnjvx0j9m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-presents-new-lorundrostat-data-in-i28nnjvx0j9m.html?utm_source=stocktitan-bluesky&utm_medium=social
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 22, 2026 at 10:40 PM
#MLYS Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Wee…
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-presents-new-lorundrostat-data-in-i28nnjvx0j9m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-presents-new-lorundrostat-data-in-i28nnjvx0j9m.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $MLYS
Peterson Kristine (Insider) reported special transactions (Non-P/S).
Peterson Kristine (Insider) reported special transactions (Non-P/S).
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 20, 2026 at 9:35 PM
🚨 $MLYS
Peterson Kristine (Insider) reported special transactions (Non-P/S).
Peterson Kristine (Insider) reported special transactions (Non-P/S).
🚨 $MLYS
COATS LONNEL (Insider) reported special transactions (Non-P/S).
COATS LONNEL (Insider) reported special transactions (Non-P/S).
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 20, 2026 at 9:33 PM
🚨 $MLYS
COATS LONNEL (Insider) reported special transactions (Non-P/S).
COATS LONNEL (Insider) reported special transactions (Non-P/S).
🚨 $MLYS
Peterson Kristine (Insider) filed Form 3 reporting no initial stock ownership.
Peterson Kristine (Insider) filed Form 3 reporting no initial stock ownership.
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 20, 2026 at 9:34 PM
🚨 $MLYS
Peterson Kristine (Insider) filed Form 3 reporting no initial stock ownership.
Peterson Kristine (Insider) filed Form 3 reporting no initial stock ownership.
🚨 $MLYS
COATS LONNEL (Insider) filed Form 3 reporting no initial stock ownership.
COATS LONNEL (Insider) filed Form 3 reporting no initial stock ownership.
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 20, 2026 at 9:30 PM
🚨 $MLYS
COATS LONNEL (Insider) filed Form 3 reporting no initial stock ownership.
COATS LONNEL (Insider) filed Form 3 reporting no initial stock ownership.
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
->BioSpace | More on "Lorundrostat for hypertension and kidney disease" at BigEarthData.ai | #disease #data #health
->BioSpace | More on "Lorundrostat for hypertension and kidney disease" at BigEarthData.ai | #disease #data #health
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
In participants with CKD, lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD RADNOR, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today presented new clinical data for lorundrostat at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. The data were shared in an oral presentation delivered by Liffert Vogt, MD, PhD. In this analysis, lorundrostat provided statistically significant and clinically meaningful reductions in systolic blood pressure (SBP) that were similar between participants with Stages 1 to 3 CKD and those without CKD. At week 12, lorundrostat reduced placebo-adjusted SBP by 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). In participants with CKD, SBP reductions were seen as early as week 2. A greater proportion of lorundrostat-treated participants reached the target SBP below 130 mmHg at week 12 compared with placebo, both among participants with CKD (44% vs. 18%) and those without CKD (48% vs...
www.biospace.com
October 23, 2026 at 6:49 AM
🚨 $MLYS
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
SEC Filing: MLYS
Click to view the official SEC document.
www.sec.gov
October 19, 2026 at 8:44 PM
🚨 $MLYS
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
$DHR-1 $ZETA-1 $BTI-1 $DERM-1 $CLDX-1 $UDR-1 $MLYS-1 $CHWY-1 $CSX-1 $FRO-1 $NIQ-1 $CMCSA-1 $U-1 $ZSL-1 $SYRE-1 $LSCC-1 $MCHP-1 $COP-1 $QLD-1 $EVSM-1 $TZA-1 $HON-1 $XLI-1 $CGSM-1 $SCHW-1
Daily Wrap - Final Message: Daily Wrap up for 2026-10-20 - 1307 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-10-20 - 1307 events.
#burst_trades #HFT #trading ...
October 20, 2026 at 8:12 PM
$DHR-1 $ZETA-1 $BTI-1 $DERM-1 $CLDX-1 $UDR-1 $MLYS-1 $CHWY-1 $CSX-1 $FRO-1 $NIQ-1 $CMCSA-1 $U-1 $ZSL-1 $SYRE-1 $LSCC-1 $MCHP-1 $COP-1 $QLD-1 $EVSM-1 $TZA-1 $HON-1 $XLI-1 $CGSM-1 $SCHW-1
Daily Wrap - Final Message: Daily Wrap up for 2026-10-20 - 1307 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-10-20 - 1307 events.
#burst_trades #HFT #trading ...
Mineralys Therapeutics CEO Jon Congleton Sells $1.9M in MLYS Shares
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approx…
Read more: https://embers.news/article/mineralys-therapeutics-ceo-jon-congleton-sells-19m-in-mlys-shares-503721
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approx…
Read more: https://embers.news/article/mineralys-therapeutics-ceo-jon-congleton-sells-19m-in-mlys-shares-503721
Mineralys Therapeutics CEO Jon Congleton Sells $1.9M in MLYS Shares
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approximately $1.9 million. The transaction occurs as the biotechnology firm advances toward a potential commercial launch for its lead hypertension candidate, lorundrostat.
embers.news
October 18, 2026 at 5:20 PM
Mineralys Therapeutics CEO Jon Congleton Sells $1.9M in MLYS Shares
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approx…
Read more: https://embers.news/article/mineralys-therapeutics-ceo-jon-congleton-sells-19m-in-mlys-shares-503721
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approx…
Read more: https://embers.news/article/mineralys-therapeutics-ceo-jon-congleton-sells-19m-in-mlys-shares-503721
#$MLYS daily chart
Friday -6.2% to $20.30 on 1.18M shares.
Closed below the prior 52w low. ASN window Oct 21–25; PDUFA Dec 22.
Hub: www.merlintrader.com/mineralys-th...
Friday -6.2% to $20.30 on 1.18M shares.
Closed below the prior 52w low. ASN window Oct 21–25; PDUFA Dec 22.
Hub: www.merlintrader.com/mineralys-th...
October 18, 2026 at 10:24 AM
#$MLYS daily chart
Friday -6.2% to $20.30 on 1.18M shares.
Closed below the prior 52w low. ASN window Oct 21–25; PDUFA Dec 22.
Hub: www.merlintrader.com/mineralys-th...
Friday -6.2% to $20.30 on 1.18M shares.
Closed below the prior 52w low. ASN window Oct 21–25; PDUFA Dec 22.
Hub: www.merlintrader.com/mineralys-th...
📅 CATALYST REMINDER | #$MLYS
October 21–25, 2026 (conference window) — Clinical Data Presentation
Launch-HTN lorundrostat data in CKD (blood pressure, albuminuria) at ASN Kidney Week; session day not given.
🔗 Full details: www.merlintrader.com/mineralys-th...
#MLYS #Biotech
October 21–25, 2026 (conference window) — Clinical Data Presentation
Launch-HTN lorundrostat data in CKD (blood pressure, albuminuria) at ASN Kidney Week; session day not given.
🔗 Full details: www.merlintrader.com/mineralys-th...
#MLYS #Biotech
Mineralys $MLYS: Lorundrostat, FDA Review And Risks
Mineralys stock analysis: December 22 lorundrostat PDUFA, hypertension trial evidence, Baxfendy competition, cash, debt and commercial risks.
www.merlintrader.com
October 17, 2026 at 5:17 PM
📅 CATALYST REMINDER | #$MLYS
October 21–25, 2026 (conference window) — Clinical Data Presentation
Launch-HTN lorundrostat data in CKD (blood pressure, albuminuria) at ASN Kidney Week; session day not given.
🔗 Full details: www.merlintrader.com/mineralys-th...
#MLYS #Biotech
October 21–25, 2026 (conference window) — Clinical Data Presentation
Launch-HTN lorundrostat data in CKD (blood pressure, albuminuria) at ASN Kidney Week; session day not given.
🔗 Full details: www.merlintrader.com/mineralys-th...
#MLYS #Biotech